Malignant astrocytoma is one of the most common and deadly primary central nervous system tumors of childhood. Most affected children exhibit relentless disease progression despite a combination of surgical and adjuvant treatment and die within several months of diagnosis; however, 30 to 40 percent respond favorably to such therapy and appear to be cured. The basis for the widely differing outcomes in children with malignant astrocytomas has been largely an enigma, even taking into account clinical prognostic factors, which has hampered efforts at therapeutic stratification. In preliminary studies, the investigators hypothesized that molecular and immunohistochemical markers of tumor biology would provide a means for supplementing clinical and histological information as a way to refine prognostic assessments. To test their hypothesis, the investigators conducted a retrospective institutional study investigating the prognostic utility of a variety of potential markers in a cohort of well-characterized pediatric high- grade gliomas. Their preliminary data indicated a strong association between progression-free and overall survival and p53 mutation and expression status, MIB-1 proliferation index, and basic fibroblast growth factor immunoreactivity in children with these tumors. In the current study, the authors propose to test further the validity of their hypothesis by examining the prognostic utility of a selected panel of immunohistochemical and genotypic markers in a larger cohort of childhood malignant gliomas to define conclusively factors that are independently predictive of outcome. The investigators are in a unique position to address this issue, both because of institutional expertise in tumor marker studies and because of their access to the histological specimens of the largest multi-institutional cohort of children with malignant gliomas accrued to date (Childhood Cancer group (CCG) study 945). Their cohort study is endorsed by the CCG (study designated as CCG-B0051), who will be providing statistical support and specimen retrieval.
The aims of this study are: 1) to determine whether TP53 mutations have an adverse association with therapeutic outcome; 2) to determine whether MIB-1 proliferative index supplements histology as a predictor of outcome; and 3) to examine the applicability of other potential markers, particularly basic FGF and bcl-2 overexpression and chromosome 10 deletion, as correlates of tumor behavior. These data will be evaluated in the context of other prognostic factors to develop a means for biologically stratifying malignant gliomas. Taken together, this work would provide new insights into the biological correlates of glioma behavior and would establish a basis for identifying groups of patients who may respond poorly to current therapy and might be appropriate candidates for therapeutic approaches.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS037704-02
Application #
2892423
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Program Officer
Jacobs, Tom P
Project Start
1998-09-01
Project End
2001-05-31
Budget Start
1999-06-01
Budget End
2000-05-31
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Neurosurgery
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Bouffet, Eric; Allen, Jeffrey C; Boyett, James M et al. (2016) The influence of central review on outcome in malignant gliomas of the spinal cord: the CCG-945 experience. J Neurosurg Pediatr 17:453-9
Nikiforova, Marina N; Wald, Abigail I; Melan, Melissa A et al. (2016) Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro Oncol 18:379-87
Jakacki, Regina I; Cohen, Kenneth J; Buxton, Allen et al. (2016) Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. Neuro Oncol 18:1442-50
Eisenstat, David D; Pollack, Ian F; Demers, Alain et al. (2015) Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945. J Neurooncol 121:573-81
Batra, Vandana; Sands, Stephen A; Holmes, Emi et al. (2014) Long-term survival of children less than six years of age enrolled on the CCG-945 phase III trial for newly-diagnosed high-grade glioma: a report from the Children's Oncology Group. Pediatr Blood Cancer 61:151-7
Joshi, Kaushal; Banasavadi-Siddegowda, Yeshavanth; Mo, Xiaokui et al. (2013) MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells 31:1051-63
Mao, Ping; Joshi, Kaushal; Li, Jianfeng et al. (2013) Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci U S A 110:8644-9
Pollack, Ian F; Jakacki, Regina I; Butterfield, Lisa H et al. (2013) Ependymomas: development of immunotherapeutic strategies. Expert Rev Neurother 13:1089-98
Horbinski, Craig; Nikiforova, Marina N; Hagenkord, Jill M et al. (2012) Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol 14:777-89
Cohen, Kenneth J; Pollack, Ian F; Zhou, Tianni et al. (2011) Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol 13:317-23

Showing the most recent 10 out of 40 publications